$GMED

GLOBUS MEDICAL INC

Globus Medical is a medical device company headquartered in Audubon, Pennsylvania. It develops and commercializes healthcare solutions for patients with musculoskeletal disorders, serving hospitals, ambulatory surgery centers and physicians. The business is managed globally within one reportable segment, with products and services grouped into Musculoskeletal Solutions and Enabling Technologies. Globus sells through direct sales representatives and exclusive independent distributors in the U.S. and internationally; it also sells hip and knee products primarily through independent sales agents. Musculoskeletal Solutions include spinal and orthopedic implants, biologics, surgical instruments, spinal cord stimulation therapy and neuromonitoring services. Enabling Technologies include imaging, navigation and robotics systems for assisted surgery, such as the ExcelsiusGPS® robotic guidance and navigation platform, and surgical planning software. Globus also offers capital equipment through sales and leasing arrangements. Its products are used in spinal, orthopedic and neurosurgical procedures, while its neuromonitoring services support spine and brain-related surgeries.

0
1
1
—
$3.6M
TOBIN JAMES R
33%
See all $GMED insider activity →
Low

Can Globus Medical Stock Rally 30% After This Dip?

Globus Medical (GMED) shares fell 19.1% since November 4, 2026, after lowering its 2026 revenue forecast. Historically, the stock has rallied a median 39.3% within a year after similar drops. Revenue declined 0.7% in Q3 2026, with full-year revenue forecast cut to $3.09B. Management expects new products to drive growth in 2027.

Globus Medical Director Sold Shares Worth Over $3.1M

Globus Medical director Tobin James R sold 41,666 shares in two transactions on November 10, 2026, totaling $3,131,547. He no longer owns Class A Common Stock, according to an SEC filing.

TOBIN JAMES R sold $3.1M of GMED

TOBIN JAMES R sold 41,666 shares of GLOBUS MEDICAL INC (GMED) at an average of $75.16 ($75.10–$75.68, $3.13M total) across 2 trades on 2026-11-10.

GMED sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning GMED (GLOBUS MEDICAL INC). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.

Recent GMED coverage spans earnings, financial news and insider activity.

In the last 30 days, GMED insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($3.6M). The most active reporter was TOBIN JAMES R with 2 filings. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving GMED

AlphAI scores every news story that mentions GMED with an AI model for sentiment and relevance, and aggregates insider trades from GLOBUS MEDICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GMED

Score

Can Globus Medical Stock Rally 30% After This Dip?

Globus Medical (GMED) shares fell 19.1% since November 4, 2026, after lowering its 2026 revenue forecast. Historically, the stock has rallied a median 39.3% within a year after similar drops. Revenue declined 0.7% in Q3 2026, with full-year revenue forecast cut to $3.09B. Management expects new products to drive growth in 2027.

Should You Buy Globus Medical Stock For Its Cash?

Globus Medical (GMED) generated free cash flow of 7.9% of its market value over the last twelve months, higher than the S&P 500 median. Despite a 17.5% stock drop, its cash flow increased to $757 million. Revenue growth has slowed, with Q3 2026 revenue down 0.7% YoY. Management cut its 2026 revenue forecast but maintained EPS guidance. The company has low debt and high operating margins.

Globus Medical (GMED) Q3 2026 Earnings Call Transcript

Globus Medical (GMED) reported Q3 2026 revenue of $763.7M, down 0.7% YoY. Non-GAAP EPS was $1.23, up 4%. Free cash flow hit a record $225M. U.S. Spine grew 2%, while Nevro declined 26%. The company expects growth from new product launches in 2027, including SCRIPT implants and EIQ suite. Trauma business grew 19%.

Globus Medical: Q3 Earnings Snapshot

Globus Medical Inc. (GMED) reported Q3 profit of $141.2M, or $1.04 per share, beating earnings estimates of $1.20 per share. Revenue was $763.7M, missing forecasts of $793M. The company expects full-year earnings of $4.95-$5.05 per share and revenue of $3.09B.

$GMEDMedEarnings

Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program

GLOBUS MEDICAL INC (GMED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program AUDUBON, PA., November 5, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial resu

Related tickers